New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
07:40 EDTHTWR, THORHeartWare remains well positioned in LVAD market, says Leerink
Leerink attributes HeartWare's (HTWR) disappointing Q4 sales to company-specific issues and broader market weakness. The firm expects competitor Thoratec (THOR) to trade lower on the potential for LVAD market weakness, but keeps Outperform ratings on companies. Leerink still views Thoratec as well positioned in the LVAD market and sees potential catalysts in 2014.
News For HTWR;THOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
07:35 EDTTHORThoratec sees Q3 revenue $102M-$107M, consensus $109.54M
Subscribe for More Information
07:34 EDTTHORThoratec appoints Keith Grossman President and CEO
Subscribe for More Information
September 17, 2014
11:41 EDTHTWR, THORLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use